Literature DB >> 33839707

COVID-19 in the MENA Region: Facts and Findings.

Nour K Younis1, Mira Rahm2, Fadi Bitar1, Mariam Arabi3.   

Abstract

INTRODUCTION: Our study aims to assess the prevalence of COVID-19 in the Middle East and North Africa (MENA) region. It aims also to examine the various factors that have led to the unequal distribution of the confirmed cases among the different MENA countries.
METHODOLOGY: Data was retrieved from the World Health Organization situation reports issued between January 29 and June 5, 2020. It included the numbers of cumulative cases, new cases, and cumulative deaths reported by MENA countries. Similarly, we searched for relevant articles in PubMed and Medline.
RESULTS: A total of 481,347 cases and 11,851 deaths occurred in the MENA region, accounting for 7.37% and 3.06% of the global cases and deaths respectively. Iran had the highest number of cases and deaths accounting for 34.1% and 68.1% of the MENA cases and deaths respectively. Together the Gulf Cooperation Council (GCC) countries accounted for 52.2% and 10.6% of MENA cases and deaths respectively. Egypt had the highest number of confirmed cases and deaths among the African countries of the region. Syria, Libya and Yemen (countries at war) had the lowest numbers of reported cases. The MENA region overall case fatality rate (CFR) was estimated at 2.46%. The highest CFR (22.75%) occurred in Yemen, and the lowest (0.07%) in Qatar.
CONCLUSIONS: The unequal distribution of wealth among the MENA countries, the lack of sociopolitical stability, and the high number of undetected and underreported cases in some of them have resulted in varied incidences of COVID-19 related morbidity and mortality. Copyright (c) 2021 Nour K Younis, Mira Rahm , Fadi Bitar, Mariam Arabi.

Entities:  

Keywords:  COVID-19; MENA; coronavirus; incidence

Year:  2021        PMID: 33839707     DOI: 10.3855/jidc.14005

Source DB:  PubMed          Journal:  J Infect Dev Ctries        ISSN: 1972-2680            Impact factor:   0.968


  4 in total

Review 1.  COVID-19: potential therapeutics for pediatric patients.

Authors:  Nour K Younis; Rana O Zareef; Ghina Fakhri; Fadi Bitar; Ali H Eid; Mariam Arabi
Journal:  Pharmacol Rep       Date:  2021-08-30       Impact factor: 3.024

Review 2.  Aspirin in COVID-19: Pros and Cons.

Authors:  Rana Zareef; Marwa Diab; Tala Al Saleh; Adham Makarem; Nour K Younis; Fadi Bitar; Mariam Arabi
Journal:  Front Pharmacol       Date:  2022-03-10       Impact factor: 5.810

3.  Outcome and characteristics of COVID-19 patients associated with stroke: a multicenter hospital-based study in Egypt.

Authors:  Ahmed H Elsheshiny; Hussein Awad El Gharieb; Mostafa Ahmed Sabrh
Journal:  Egypt J Neurol Psychiatr Neurosurg       Date:  2022-07-07

Review 4.  Syndemic aspects between COVID-19 pandemic and social inequalities.

Authors:  Jonathan Santos Apolonio; Ronaldo Teixeira da Silva Júnior; Beatriz Rocha Cuzzuol; Glauber Rocha Lima Araújo; Hanna Santos Marques; Isadora de Souza Barcelos; Luana Kauany de Sá Santos; Luciano Hasimoto Malheiro; Vinícius Lima de Souza Gonçalves; Fabrício Freire de Melo
Journal:  World J Methodol       Date:  2022-09-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.